Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a radiopharmaceutical-focused company whose news flow centers on diagnostic imaging products, radiopharmaceutical pipeline progress and corporate developments. The company describes its purpose as enabling clinicians to "Find, Fight and Follow" disease, and its announcements frequently highlight advances in PET radiodiagnostics, oncology imaging agents and Alzheimer’s disease diagnostics.
News about Lantheus often covers regulatory milestones for its radiopharmaceutical pipeline. Recent releases include U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application for a new formulation of its piflufolastat F 18 PSMA PET imaging agent, a PDUFA date for LNTH-2501 (Ga 68 edotreotide) for somatostatin receptor-positive neuroendocrine tumors, and FDA acceptance of an NDA for MK-6240, a tau-targeted PET imaging agent for Alzheimer’s disease. These updates provide insight into how the company is expanding its diagnostic portfolio in oncology and neurology.
Lantheus news also frequently addresses business development and portfolio shaping. The company has reported acquisitions of Evergreen Theragnostics and Life Molecular Imaging, adding assets such as OCTEVY and Neuraceq and expanding its capabilities across the radiopharmaceutical value chain. It has also announced the divestiture of its SPECT business to SHINE Technologies, along with licensing agreements such as an exclusive deal with GE HealthCare to develop, manufacture and commercialize PYLARIFY in Japan.
Investors and healthcare professionals following LNTH news can also expect quarterly earnings releases, stock repurchase program announcements, leadership transition updates and conference participation notices. Together, these items provide context on Lantheus’ financial performance, capital allocation, governance and strategic direction in the radiopharmaceutical and medical imaging space.
Lantheus Holdings has announced its Inaugural Investor Day, scheduled for May 17, 2022, where it will outline its long-term growth strategy and financial targets. The event will feature updates from the management team on key commercial products and development assets. CEO Mary Anne Heino expressed enthusiasm for providing insights into their business and growth strategies aimed at delivering long-term value for patients and shareholders. The live webcast will be accessible for replay post-event.
Lantheus Holdings (NASDAQ: LNTH) released findings from a retrospective study analyzing the use of its PYLARIFY® AI in monitoring treatment response in prostate cancer patients. The study demonstrated that changes in PSMA scan indices correlated significantly with prostate-specific antigen (PSA) responses post-androgen deprivation therapy. Patients exhibited a 97% average decline in PSA levels, paired with significant reductions in PSMA indices in lymph nodes and bone. These results suggest PYLARIFY AI may enhance the quantification of disease burden and response to therapy in prostate cancer management.
Lantheus Holdings announced the initiation of a Phase 2 trial for NM-01, a technetium-99m SPECT imaging agent aimed at assessing PD-L1 expression in non-small cell lung cancer (NSCLC). The PELICAN trial will evaluate NM-01's ability to identify responders to checkpoint inhibitor therapies compared to traditional immunohistochemistry methods. Conducted in partnership with NanoMab Technology at King’s College London, this trial seeks to improve patient selection for treatment and offers a non-invasive alternative to biopsies. The outcome could enhance treatment efficacy and minimize unnecessary side effects.
Lantheus Holdings has announced updates from the National Comprehensive Cancer Network (NCCN) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) regarding the use of PYLARIFY® (piflufolastat F 18) for prostate cancer. The guidelines now include PYLARIFY as a recommended agent for patient selection in PSMA-targeted radioligand therapy. This follows PYLARIFY's FDA approval and aims to enhance access to targeted treatments for patients with advanced prostate cancer.
NORTH BILLERICA, Mass., May 10, 2022 – Lantheus Holdings (NASDAQ: LNTH) announced that President and CEO Mary Anne Heino, along with CFO Bob Marshall, will present at the UBS Global Healthcare Conference. The presentation is scheduled for 8:30 a.m. ET on May 24, 2022, in New York. Investors can access a live webcast through the Company’s website, with a replay available for 30 days post-event. Lantheus is known for its innovative imaging diagnostics and AI solutions aimed at serious medical conditions.
Lantheus Holdings reported a remarkable first quarter of 2022 with worldwide revenue of $208.9 million, a 125.8% increase from the previous year. The company's GAAP net income surged to $43.0 million or $0.61 per share, up from $9.0 million or $0.13 per share in Q1 2021. Adjusted fully diluted EPS rose to $0.97, significantly higher than $0.05 a year prior. The company also provided a Q2 revenue guidance of $200 million - $215 million and updated its full-year revenue guidance to $800 million - $835 million.
Lantheus Holdings (NASDAQ: LNTH) will host a conference call on April 29, 2022, at 8:00 a.m. ET to discuss its Q1 2022 financial and operating results. Investors can access the call via telephone or through a live webcast on the company's investor website. A replay will be available two hours post-call for 30 days. Lantheus, based in North Billerica, Massachusetts, specializes in imaging diagnostics and therapeutics, with a diverse product portfolio including DEFINITY®, PYLARIFY®, and RELISTOR®.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced the appointment of Jean-Claude Provost, MD, as Interim Chief Medical Officer, effective immediately. With over 30 years of experience in drug and diagnostic agent development, Dr. Provost's prior roles include leadership positions at GE Healthcare and Pfizer. His extensive background in radiopharmaceuticals and clinical research is expected to enhance Lantheus' strategic vision. President and CEO Mary Anne Heino expressed confidence in Dr. Provost's capabilities to drive the company's innovative solutions aimed at improving patient outcomes.
Lantheus Holdings announced a collaboration with Novartis to include PYLARIFY® (piflufolastat F18) in clinical trials for Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) targeting prostate cancer. This partnership aims to explore how PSMA PET imaging agents can enhance patient access to PSMA-targeted therapies.
The U.S. Total Addressable Market for PSMA PET imaging is now estimated at approximately $1.1 billion, an increase from the previous $220 million, reflecting an additional 30,000 scans per year for metastatic castration-resistant prostate cancer.
Lantheus Holdings (NASDAQ: LNTH) announced that Mary Anne Heino, President and CEO, along with Bob Marshall, CFO, will present at the Barclays Global Healthcare Conference on March 15, 2022, at 8:30 a.m. ET in Miami, FL. Investors can access a live webcast of the presentation through the Investors section on the company’s website, with a replay available for 30 days afterward. Lantheus provides innovative imaging diagnostics and therapeutics, focusing on serious medical conditions.